Identifying Barriers to Sglt2 Inhibitor Use in Eligible Patients With Heart Failure: A Real-World Experience From a Single Centre

Dhaliwal, Amandeep; Kochan, A; Didi, Ahmad; Toma, Mirela Mărioara

doi:10.1016/j.cjca.2021.07.119

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical data from 16 4 teaching hospitals in Korea showed that older adults (>65 years) and those recently hospitalized were least likely to receive SGLT-2i; however, the reasons for these disparities are not clear, highlighting limitations of administrative data for understanding barriers to care. At the patient 17 level, a study of a heart failure clinic identified that patient preference and inability to afford the medications were common barriers to use. At the system level, cost and approval processes were 14,15 identified barriers.…”

Section: Optimizing Uptakementioning

confidence: 99%

Increasing Societal Benefit From Cardiovascular Drugs

Straus

2022

Circulation

View full text Add to dashboard Cite

During the past few years, several innovative treatments for noncommunicable chronic disease have become available, including SGLT2i (sodium-glucose cotransporter-2 inhibitors), GLP-1a (glucagon-like-peptide 1 agonists), ARNI (angiotensin receptor-neprilysin inhibitors), and finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist. Each of these medications improves clinically relevant outcomes when added to existing therapies, and the indications for their use are rapidly expanding. Because existing drug regimens are already complex and costly, ensuring that society derives the maximal benefit from these new agents represents a major challenge. This Primer discusses how society can meet this challenge, which we address in terms of 5 principles: maximizing benefit, minimizing harm, optimizing uptake, increasing value for money, and ensuring equitable access. The Primer is most relevant for stakeholders in high-income countries, but the principles are broadly applicable to stakeholders in other settings, including low- and middle-income countries. We have focused the discussion on SGLT-2i, but the 5 principles herein could be used with reference to ARNI, finerenone, or any other health product.

show abstract